Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group - Test2 - elhamkhani - TriplyDB

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

http://www.wikidata.org/entity/Q27861083

about

Viral hepatitis and hepatocellular carcinoma Hepatitis C: a review for primary care physicians Aminoadamantanes versus other antiviral drugs for chronic hepatitis C Aminoadamantanes for chronic hepatitis C Aminoadamantanes versus other antiviral drugs for chronic hepatitis C Aminoadamantanes for chronic hepatitis C Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Ribavirin monotherapy for chronic hepatitis C Ribavirin plus interferon versus interferon for chronic hepatitis C New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1 The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein Clinical significance of hepatitis C virus genotypes Structure-function analysis of the 3' stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication 3' nontranslated RNA signals required for replication of hepatitis C virus RNA Antiviral actions of interferons RNA virus error catastrophe: direct molecular test by using ribavirin Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?The neurobiological bases for development of pharmacological treatments of aggressive disorders Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus Cryoglobulins Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study Physicians' preference values for hepatitis C health states and antiviral therapy: a survey Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C.Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Era of direct acting antivirals in chronic hepatitis C: Who will benefit?Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance Hepatitis C virus (HCV) infection in Africa: a review Hepatitis C virus: A global view Emerging therapies for the treatment of hepatitis C Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention Direct acting antivirals for the treatment of chronic viral hepatitis

P2860

Q21245597-5E70A36F-27A7-4CBD-AD51-B253AB51CABF Q22306040-000C1813-55B5-463F-9059-5DA21B9ADF10 Q24193940-25472096-03DA-4904-A022-DCBE4EEB82EA Q24194770-9002C6C3-EF3E-4310-B80D-618F3062608B Q24194815-E2D62DBD-B6FD-468A-9240-B304DCC1A6B6 Q24201226-D4DB2B4F-BE89-4434-8619-E2297A6D3396 Q24201588-E638F0FC-5DA2-426C-AC9B-CF456EC44601 Q24240057-D9F16246-86D9-4E43-B363-2F00ADB7C33A Q24240879-2F34FB83-74A5-4826-BB6D-DC570FB92931 Q24300907-72EE3236-3514-40D6-8ECD-A36232C4AF51 Q24307963-2DEA26AA-8685-4C7D-A81D-C580C9787391 Q24338469-D6946406-86C1-40E6-8A56-D9B822ACEC44 Q24514512-34955B84-2AC3-4701-986A-E9430C81FBD4 Q24540195-1AE96700-4655-45BF-BF71-8212543ADFAB Q24550606-3FF3E748-9B10-4D81-A1E8-610A4CBA4D78 Q24550676-5C7E7A52-1C75-49F3-960F-78E2540ABF37 Q24599371-E49E5E44-DF65-45F2-A79A-3061FCB15D20 Q24644729-F329E008-1E4B-4B3A-96CB-ABD268F55BFC Q24651612-9150BF9D-3BFB-40E9-A0DB-704EC773F30A Q24658111-AFE2D608-0C0B-4289-BABE-DCAB0E42B36C Q24673191-B75C7D31-1F1F-45BF-BE4D-FCD8C9686951 Q24680380-0DEE5985-55A8-46A6-B357-386D0FCD4E2E Q24681387-73AF3541-73CD-4EAE-832A-E05A8BE84AF5 Q24683611-E2C5F12C-C5FF-4F33-BFFB-D5EB5FAEAD2E Q24791398-23E9526E-E3C6-451E-B251-C411929812D3 Q24797971-6C69E522-5DDD-4D1E-B0A0-1EBBCED7B9A3 Q24799021-BC6CA7CB-7F3B-4C56-A4DD-A9A1D29897B1 Q24799492-1DF9BBC9-0AB0-448F-A7D3-2F650CAEEC8C Q24802683-C3C54E12-37AC-4613-BD9B-867CC7F46861 Q24804388-2114481B-1CD0-4827-8A34-3A98A7D7D0F7 Q24813993-44417132-1F8F-4513-A5BC-BFBFE94AA855 Q26746563-841056F9-76B6-4BCB-BADB-247A0B252F51 Q26777506-79297B1F-7D51-4901-BA4D-D80458D798D2 Q26777659-D5CA62A8-054E-45E8-B8E6-9FD78F4DE008 Q26824322-84FA0419-0E1E-4D73-8965-9AD42703ECE9 Q26862531-D72BD2B4-9A79-47FD-AA4A-FB73FDC01F47 Q27003319-68EA0DFB-1A76-4957-A96A-97CB369B7609 Q27010548-FC40E841-C8CB-461B-838A-61E956DD88D3 Q27014761-37054865-F1EB-46DC-9C23-D708C989717E Q27022216-11C7058F-0225-4E7A-A94E-36CD57BE811C

P2860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

http://www.wikidata.org/entity/Q27861083

description

1998 nî lūn-bûn

@nan

1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@ast

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@en

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@nl

type

label

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@ast

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@en

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@nl

prefLabel

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@ast

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@en

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@nl

P1433

Q27861083-78744BAE-A047-4EA1-883A-A3C91EA34CD8

P1476

Q27861083-C92B1F61-9C0D-41D0-AA3C-C4C73271DCB6

P2093

Q27861083-4DDEEF44-A14B-437B-9F6C-1F07696B204D

Q27861083-69265C9E-3642-4185-B726-4B0779E23C53

Q27861083-694B6714-2D63-445E-97B3-4F9FCE132303

Q27861083-6FCE7A79-6186-4346-A522-377C46870D8F

Q27861083-7B26F77E-EB18-4875-B9A7-64DEBA1A957E

Q27861083-802B62AE-B71A-4642-A3BB-9E8EF331B52D

Q27861083-9063FF1E-A072-4ED2-8A55-E74B9CF6DAE4

Q27861083-C70AEF85-C815-48D9-9179-5735AB43635E

Q27861083-C7CEE89B-7507-4EAC-9B6A-F9A3CEE9D3EC

Q27861083-CCA24A87-F7E6-4A86-97B6-240DFB7F4FE5

P304

Q27861083-7D891DB8-DD21-40B4-87EE-2E5E529D00A8

P31

Q27861083-7699BABC-11EE-495E-AEF9-951CE2FA136A

P3181

Q27861083-3E5E1EFC-8962-457B-B2E0-D11A0D3A6717

P356

Q27861083-744C3127-4156-4E0D-B0D7-AA69DADE8843

P407

Q27861083-117EB8C4-1965-4E64-9838-95F8AE9DBD5D

P433

Q27861083-128304DC-A70B-4E55-BEE5-54D6E51AF061

P478

Q27861083-CA2BBFFB-A4B0-4B08-9522-45665B2E68D2

P577

Q27861083-CB2E8F5F-56F0-4129-9B49-DCE57649438C

P698

Q27861083-5C49F40B-F7E3-40FC-8E34-C4F246CA69A3

P921

Q27861083-8c8d6d07-41d8-7f4b-1854-219df3ec2822

P3181

P356

NEJM199811193392101

P1433

The New England Journal of Medicine

P1476

Interferon alfa-2b alone or in ...... s Interventional Therapy Group

@en

P2093

E R Schiff

http://www.w3.org/2001/XMLSchema#string

J G McHutchison

http://www.w3.org/2001/XMLSchema#string

J K Albrecht

http://www.w3.org/2001/XMLSchema#string

M H Ling

http://www.w3.org/2001/XMLSchema#string

M L Shiffman

http://www.w3.org/2001/XMLSchema#string

S C Gordon

http://www.w3.org/2001/XMLSchema#string

S Cort

http://www.w3.org/2001/XMLSchema#string

V K Rustgi

http://www.w3.org/2001/XMLSchema#string

W M Lee

http://www.w3.org/2001/XMLSchema#string

Z D Goodman

http://www.w3.org/2001/XMLSchema#string

P304

1485-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

761074

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199811193392101

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

339

http://www.w3.org/2001/XMLSchema#string

P577

1998-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9819446

http://www.w3.org/2001/XMLSchema#string

P921